Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P330. Cyclosporin A as rescue therapy for steroid-refractory acute severe ulcerative colitis: Oral administration is as effective as intravenous
P330. Epidemiology of pediatric chronic inflammatory bowel disease in Serbia, 2005–2009
P330. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of elevated myeloid lineage leucocytes as mono-therapy or in combination with low dose prednisolone
Authors:

T. Tanaka1, S. Sugiyama1, H. Goishi1, H. Yamada1, 1Akitsu Prefectural Hospital, Hiroshima, Japan

P330

Efficacy and safety of vedolizumab with advancing age in patients with Crohn's disease: Results from the GEMINI 2 study

Authors:

V. Yajnik*1, N. Khan2, M. Dubinsky3, J. Axler4, A. Green5, B. Abhyankar6, K. Lasch7

1Massachusetts General Hospital, Harvard Medical School, Gastroenterology, Boston, MA, United States, 2University of Pennsylvania, Perelman School of Medicine, Medicine, Philadelphia, Pennsylvania, United States, 3Mount Sinai Hospital, Pediatric Gastroenterology, New York, United States, 4Toronto Digestive Disease Associates, University of Toronto, Gastroenterology, Toronto, Canada, 5Takeda Global Research & Development Centre (Europe) Ltd., Statistics, London, United Kingdom, 6Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom, 7Takeda Pharmaceuticals International Inc., Medical Affairs, Deerfield, IL, United States

P331.

The elimination of cytomegalovirus in patients with ulcerative colitis without antiviral therapy

Authors:

O. Knyazev1, I. Ruchkina1, A. Konoplyannikov2, N. Schakhpazyan3, A. Parfenov1, 1Central Research Institute of Gastroenterology, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, 2Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation, 3Russian oncological scientific center, Laboratory of Stem Cells, Moscow, Russian Federation

P331. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis in The Netherlands
P331. Role of infliximab as rescue therapy in hospitalised patients with severe, steroid refractory ulcerative colitis. Local experience. Liverpool and Bankstown hospitals, South Western Sydney Local Health District. Australia
P331. Total, free and bioavailable 25(OH) vitamin D inversely correlate with faecal calprotectin in patients with inflammatory bowel disease
Authors:

M. Garg1, O. Rosella2, J. Lubel1, P. Gibson2, 1Monash University, Gastroenterology, Eastern Health, Box Hill, Australia, 2Monash University, Gastroenterology, The Alfred Hospital, Prahran, Australia

P331

Endoscopic Balloon Dilation Delays the Need for Subsequent Surgery in Patients With Strictures In Crohn's Disease Even In Ileocolonic Anastomotic (ICA) Localization ?

Authors:

S. Hulagu, O. Senturk, G. Sirin*, A. Celebi

Kocaeli University, Gastroenterology, Kocaeli, Turkey

P332.

The efficacy of tonsil-derived mesenchymal stem cell in acute murine colitis model

Authors:

N. Sun-Kyung, J. Sung-Ae, S. Eun Mi, Y. Hye-Won, R. Jae-In, L. Min-jin, K. Seong-Eun Kim, J. Hye-Kyung, S. Ki-Nam, K. Tae Hun, Y. Kwon, M. Il Hwan, Ewha Womans University School of Medicine, Ewha Medical Research Institute, Department of Internal Medicine, Seoul, Korea, Republic of

P332. Adherence to anti-tumor necrosis factor alpha therapies in inflammatory bowel diseases: Experience from four referral Italian centers
P332. Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European collaborative follow-up study
P332. To identify various profiles of IBD patients and differences in HRQOL
Authors:

S. Jäghult1, D. Andersson1, F. Saboonchi1, 1Karolinska Institutet Danderyds sjukhus, Department of Clinical Sciences, Stockholm, Sweden

P332

Impact of Inflammatory Bowel Disease on Japanese patients' lives: International comparison of patients' views

Authors:

F. Ueno*1, Y. Nakayama2, E. Hagiwara2, O. Mikami3, A. Inamine-Sasaki3, T. Hibi4

1Ofuna Chuo Hospital, Department of Medicine, Kamakura, Kanagawa, Japan, 2IBD Network, Sapporo, Hokkaido, Japan, 3AbbVie GK, Medical Affiars, Medical, Tokyo, Japan, 4Kitasato Institute Hospital, Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan

P333.

The development of coordinated care pathways and feasibility testing in inflammatory bowel disease management

Authors:

W. van Deen, J. Choi, E. Inserra, L. Eimers, E. Kane, M. Ovsiowitz, A. Centeno, M. van Oijen, B. Roth, D. Hollander, W. Ho, D. Cole, T. Getzug, L. Connoly, A. Ho, C. Ha, E. Esrailian, D.W. Hommes, UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, Los Angeles, United States

P333. Endotoxin levels and juvenile inflammatory bowel disease – A case–control study
P333. Thrombocytosis and iron deficiency in inflammatory bowel disease patients: a mutual relationship
Authors:

E. Voudoukis1, K. Karmiris1, P. Oustamanolakis2, A. Theodoropoulou1, A. Charitakis3, Z. Archontakis3, K. Giannakopoulou3, A. Sfiridaki4, G. Paspatis1, I. Koutroubakis2, 1Venizelion General Hospital, Department of Gastroenterology, Heraklion-Crete, Greece, 2University Hospital, Department of Gastroenterology, Heraklion-Crete, Greece, 3Venizelion General Hospital, Laboratory of Haematology, Heraklion-Crete, Greece, 4Venizelion General Hospital, Blood Bank, Heraklion-Crete, Greece

P333

Safety of fecal microbiota transplantation in patients with chronic colitis and immunosuppressive treatement.

Authors:

J. Frank*1, C. Högenauer1, H.-P. Gröchenig2, K.M. Hoffmann3, G. Reicht4, H.H. Wenzl1, W. Petritsch1, P.K. Kump1

1Medical University of Graz, Internal Medicine, Division of Gastroenterology and Hepatology, Graz, Austria, 2Barmherzige Brüder Hospital, Internal Medicine, St. Veit an der Glan, Austria, 3Medical University of Graz, Pediatrics, Graz, Austria, 4Barmherzige Brüder Hospital, Internal Medicine, Graz, Austria

P334.

Thalidomide associated with anti-TNF-α therapy in Crohn's disease patients who lost response to anti-TNF-α: a case series

Authors:

M.L. Scribano1, L. Cantoro2, M. Daperno3, R. Monterubbianesi1, A. Kohn1, 1A.O. San Camillo-Forlanini, Gastroenterology Unit, Rome, Italy, 2Campus Bio-Medico, University of Rome, Department of Digestive Diseases, Rome, Italy, 3A.O. Ordine Mauriziano, Gastroenterology Unit, Turin, Italy

P334. Concentration–effect relationship of infliximab in Crohn's disease: Results of a cohort study